Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 28:5:2.
doi: 10.1186/s13737-016-0031-6. eCollection 2016.

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

Alina S R Zaltzman  1 , Lauren A Glick  2 , Jeffrey S Zaltzman  3 , Michelle Nash  4 , Michael Huang  4 , G V Ramesh Prasad  3
Affiliations

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients

Alina S R Zaltzman et al. Transplant Res. .

Abstract

Background: Tacrolimus is available as twice-daily Prograf® (Tac-BID) and the once-daily formulation, Advagraf® (Tac-OD). Although therapeutically equivalent, some transplant recipients require dose adjustments to achieve similar tacrolimus trough concentrations [Tac C0] after conversion between formulations. Tacrolimus is primarily metabolized by cytochrome P450 3A5 (CYP3A5). We sought to determine whether genetic polymorphisms in the CYP3A5 enzyme; CYP3A5 *1/*1 and CYP3A5 *1/*3 (expressers) compared to CYP3A5 *3/*3 (non-expressers) could account for discrepancies in dose requirements following conversion from Tac-BID to Tac-OD.

Methods: A cohort of 60 renal transplant recipients (RTR) from our larger conversion study of 496 patients underwent additional testing for CY3A5 genetic polymorphisms. Analysis included demographics, tac dosing and [Tac C0] pre- and post-conversion and dosing changes relative to CYP3A5 genotypes. CYP3A5 genetic polymorphisms were identified through analysis of genomic DNA.

Results: Conversion from tac bid to tac OD in this cohort required a mean (SD) dose increase from 3.1 (1.0) mg/day to 3.8 (1.3) mg/day (p = 0.007), to achieve similar [Tac C0]. The *1/*3 expresser group required a greater percentage dose adjustment (56.7 %) in converting from Tac-BID to Tac-OD as compared to the *3/*3 non-expresser group (26.6 %). Similar findings were observed with the both expresser groups combined (*1/*1 &*1/*3). The expressers were significantly more highly represented in the East Asian cohort.

Conclusions: The CYP3A5 expresser polymorphism necessitates an increase in dosing upon conversion from Tac-BID to Tac-OD, with the expresser genotypes contributing significantly to this finding. Given the variability in frequency of CYP3A5 genotypes in various ethnic groups, future studies should account for both isoenzyme polymorphism and ethnicity in optimizing dosing requirements.

Trial registration: Clinical trials.gov identifier: NCT01884480.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Tacrolimus dosing (mg/day) and mean tacrolimus trough concentration (ng/ml) pre- and post-conversion
Fig. 2
Fig. 2
Tacrolimus dosing (mg/day) pre-conversion (Tac-BID) by genotype
Fig. 3
Fig. 3
Percentage tacrolimus dose increase after conversion (Tac-OD) by genotype
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007;83:1648–1651. doi: 10.1097/01.tp.0000264056.20105.b4. - DOI - PubMed
    1. Ho ET, Wong G, Craig JC, Chapman JR. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation. 2013;95:1120–1128. doi: 10.1097/TP.0b013e318284c15b. - DOI - PubMed
    1. Min SI, Ha J, Kang HG, Ahn S, Park T, Park DD, et al. Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy. American Journal of Transplantation. 2013;13:2191–97. doi: 10.1111/ajt.12274. - DOI - PubMed
    1. Tinti F, Meçule A, Poli L, Bachetoni A, Umbro I, Brunini F, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc. 2010;42:4047–48. doi: 10.1016/j.transproceed.2010.09.052. - DOI - PubMed
    1. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le Moine A, et al. Conversion Hustert E, Haberl M, Burk O from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011;91:566–569. doi: 10.1097/TP.0b013e3182098ff0. - DOI - PubMed

Associated data

LinkOut - more resources